Fei Su

Articles by Fei Su

118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)

ByFabrice Andre,Peter A. Fasching,Aleix Prat,Patrick Neven, MD, PhD,Yen-Shen Lu,Aditya Bardia, MD, MPH, FASCO,Giuseppe Curigliano,Virginia Kaklamani, MD, DSc,Pedram Razavi,Yoon Sim Yap,Fei Su,Estelle Roux,Kristyn Pantoja,Jiwen Wu,Agnes Lteif,Dejan Juric

May 12th 2026

Latest Updated Articles

Trending on CancerNetwork

One of “The Best Opportunities” for Long-Term Remission in Multiple Myeloma

What Does Priority Review Mean for Subcutaneous Amivantamab in HNSCC?

Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status

Navigating Second-Line CAR-T Candidacy and Sequencing in DLBCL

The Rationale for JAK Inhibition/PD-1 Blockade in Immune-Resistant RCC